Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741265 | 0.89 | NPC1 (0.50) | MDM2ALOX5APKDM4ENPC1RAB9A | |
| SCHEMBL4740407 | 0.89 | NPC1 (0.50) | MDM2ALOX5APKDM4ENPC1RAB9A | |
| SCHEMBL4739114 | 0.87 | NPC1 (0.51) | MDM2ALOX5APKDM4ENPC1RAB9A | |
| SCHEMBL4741309 | 0.85 | KMT2A (0.39) | ALOX5APKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL4740498 | 0.83 | CCR2 (0.41) | — | |
| SCHEMBL4739117 | 0.76 | ALDH1A1 (0.47) | KDM4EALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL4738691 | 0.73 | EGLN1 (0.59) | MDM2PTGDR2 | |
| SCHEMBL2611304 | 0.72 | HDAC6 (0.48) | MDM2ALOX5APKDM4ENPC1RAB9A | |
| SCHEMBL17540008 | 0.72 | RAB9A (0.47) | MDM2ALOX5APKDM4EALDH1A1NPC1 | |
| SCHEMBL2619341 | 0.71 | HDAC6 (0.48) | MDM2KDM4ENPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | MDM2 2479/4885ALOX5AP 2204/4885HSD11B1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.